Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) is a Delaware company limited liability company founded in December 2013- Aeglea BioTherapeutics Holdings, LLC, renamed as a limited liability company in March 2015, headquartered in Dirk, USA Austin, Saskatchewan, with 83 full-time employees, is a clinical-stage biotechnology company that designs and develops human enzyme therapies for the treatment of rare genetic diseases and cancer patients.
Aeglea Biotherapeutics (AGLE):
Aeglea Biotherapeutics is committed to the development of enzyme-based changes in the amino acid metabolism process of cancer and genetic diseases, so as to achieve the purpose of curing.
The main product candidates of Aeglea Biotherapeutics include pegzilarginase, a recombinant human arginase 1 enzyme, which is in the early clinical development stage of arginase 1 deficiency, which is caused by a significant reduction in the activity of natural arginase 1 Autosomal recessive metabolic disease caused by; and treatment of arginine-dependent cancer.
Aeglea Biotherapeutics’ preclinical pipeline products include:
- AEB4104, a recombinant human enzyme that can degrade the amino acid homocysteine and its oxidized form homocysteine;
- AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine;
- AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine;
- AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine.
Aeglea BioTherapeutics and Merck signed a clinical cooperation agreement to evaluate the combination of pegzilarginase and Merck’s anti-PD1 therapy pembrolizumab for the treatment of patients with small cell lung cancer.
Aeglea Biotherapeutics (AGLE) investment:
Aeglea submitted a prospectus to the SEC on 6/16/2015 and landed on Nasdaq on April 7, 2016. The issue price is US$10, 5 million shares are issued, and the planned fundraising is US$50 million. The stock code is AGLE.